Human immunodeficiency virus (HIV) Market Set for Rapid Growth and Trend by 2025

Market Study Report adds “PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2025” new report to its research database. The report spread across 365 pages and table and figures in it. Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.

Request Sample for Global Human immunodeficiency virus (HIV) Market Research Report @ https://www.marketstudyreport.com/request-a-sample/450279/?utm_source=OPR-AN

Human immunodeficiency virus (HIV) Market is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline?s (GSK?s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART).

This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.

The Report projects the global HIV marketplace - which, for the purposes of this report, comprises nine major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) - to experience modest growth during the forecast period. This growth will be driven primarily by the highly anticipated arrivals of novel integrase inhibitor (INI-) and protease inhibitor (PI-) based STRs, which include ViiV Healthcare’s dolutegravir/lamivudine, ViiV’s and Janssen’s dolutegravir/rilpivirine, Gilead’s bictegravir/emtricitabine/tenofovir alafenamide fumarate (TAF), Gilead’s and Janssen’s darunavir/cobicistat/emtricitabine/TAF, and ViiV?s long-acting injectable formulation composed of cabotegravir/rilpivirine. Nevertheless, looming patent expiries of high-grossing branded drugs in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with compulsory licensing and generic erosion in Brazil and China, are expected to curtail market growth.

Key Questions Answered

- How will the HIV market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) change from 2015-2025?
- What are the most promising late-stage pipeline drugs in HIV?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
- What are the remaining unmet needs in HIV treatment management?
- What drivers and barriers will affect HIV therapeutics sales in the 9MM over the forecast period?

Request Discount for Global Human immunodeficiency virus (HIV) Market Research Report @ https://www.marketstudyreport.com/check-for-discount/450279/

Scope

- Overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline HIV market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HIV therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HIV therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

For More Info on Market Research @
http://www.openpr.com/news/archive/144590/marketstudyreport-com.html

Related Reports: -

Global Neurofeedback System Market by Manufacturers, Countries, Type and Application, Forecast to 2022
Neurofeedback is a non-invasive method of direct brain function training. It is also a type of biofeedback and is therefore, also called EEG Biofeedback. It uses the electrodes (which act like tiny microphones) placed on the client's scalp to record and amplify the EEG, or brainwaves and control auditory, visual, and/or tactile feedback which allows learning to take place. This operant learning initiates self-regulation and enhances relaxation, both necessary components of good brain function.
https://www.marketstudyreport.com/reports/global-neurofeedback-system-market-by-manufacturers-countries-type-and-application-forecast-to-2022/?utm_source=RR-AN

Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Market Study Report
The Green Suite #4594,
Dover, DE 19901
United States
Phone: 1-201-355-0868
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Website: https://www.marketstudyreport.com
News: https://www.marketstudyreport.com/category/news-releases/

This release was published on openPR.